CYP19A1 and breast cancer: In line with the concept that ESR1 mutations are primarily acquired during aromatase inhibitors treatment, Allouchery et al. have recently published findings from 42 patients with early BC treated with AI for at least 2 years, showing that ESR1 mutations were not found in any of the studied patients [40].